BDTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
12.1M
+7.1%
11.3M
-36.1%
17.6M
+60.4%
11.0M
-18.2%
13.4M
R&D
7.4M
+5.6%
7.0M
+11.2%
6.3M
-15.3%
7.4M
-20.2%
9.3M
SG&A
4.7M
+9.6%
4.3M
+7.3%
4.0M
+12.0%
3.5M
-13.7%
4.1M
Operating Income
-12057000
-7.1%
-11259000
+36.1%
-17610000
-60.4%
-10978000
+18.2%
-13420000
EBITDA
-12029000
-7.1%
-11232000
-10.2%
-10196000
+6.4%
-10892000
+18.3%
-13334000
Net Income
-9905000
-9.6%
-9036000
+40.2%
-15116000
-77.9%
-8498000
+19.5%
-10561000
EPS (Basic)
$-0.17
-6.3%
$-0.16
+38.5%
$-0.26
-73.3%
$-0.15
+21.1%
$-0.19
EPS (Diluted)
$-0.17
-6.3%
$-0.16
+38.5%
$-0.26
-73.3%
$-0.15
+21.1%
$-0.19
Shares (Diluted)
57.4M
+0.2%
57.2M
-2.7%
58.8M
+3.4%
56.9M
+0.2%
56.8M
Black Diamond Therapeutics (BDTX) โ€” Financials